This phase IV trial tests the impact of standard of care enfortumab vedotin and pembrolizumab followed by removal of all or part of the bladder (cytoreductive …

Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis and Ureter Urothelial CarcinomaMetastatic Bladder Urothelial Carcinoma+4 more

~Estimated

~$10 – $6,250

Mayo ClinicNCT06764095

Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the …

Localized Renal Pelvis and Ureter Urothelial CarcinomaMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the Bone+8 more

~Estimated

~$10 – $750

University of WashingtonNCT01050504

Phase 2

MC220503 Randomized Phase II Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer 1 (ReCIPE-B1)

This phase II trial compares therapeutic plasma exchange followed by enfortumab vedotin and pembrolizumab to standard of care next-line therapy for the treatme…

Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial CarcinomaRefractory Bladder Urothelial Carcinoma+3 more

~Estimated

~$10 – $6,250

Mayo ClinicNCT07087860